Cargando…
The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC)
BACKGROUND: Triple Negative Breast Cancers (TNBCs) lack the appropriate targets for currently used breast cancer therapies, conferring an aggressive phenotype, more frequent relapse and poorer survival rates. The biological heterogeneity of TNBC complicates the clinical treatment further. We have ex...
Autores principales: | Narrandes, Shavira, Huang, Shujun, Murphy, Leigh, Xu, Wayne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753474/ https://www.ncbi.nlm.nih.gov/pubmed/29301506 http://dx.doi.org/10.1186/s12885-017-3939-4 |
Ejemplares similares
-
Gene Expression Detection Assay for Cancer Clinical Use
por: Narrandes, Shavira, et al.
Publicado: (2018) -
Neural Functions Play Different Roles in Triple Negative Breast Cancer (TNBC) and non-TNBC
por: Tan, Renbo, et al.
Publicado: (2020) -
The fate of chemoresistance in triple negative breast cancer (TNBC)
por: O’Reilly, Elma A., et al.
Publicado: (2015) -
Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC)
por: Lee, Jieun
Publicado: (2023) -
Defining triple‐negative breast cancer with neuroendocrine differentiation (TNBC‐NED)
por: Hacking, Sean M, et al.
Publicado: (2023)